Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Conditions
Platelet Aggregation
Interventions
aspirin, placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Not applicable Interventional Accepts healthy volunteers Results available

Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion

NCT04731363
Conditions
Cardiovascular Risk Factor
Interventions
xylitol, 30g, erythritol, 30g, xylitol, 5g, glucose, 30g
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Coronary Artery Disease
Interventions
Placebo Arm, Thienopyridine Therapy, Surveillance Arm
Drug · Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
19 Years and older
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Anderson, South Carolina
Conditions
Coronary Artery Disease
Interventions
Removal of Fentanyl from peri-procedural analgesia, Fentanyl, Lidocaine, Midazolam
Other · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Not listed Phase 4 Interventional Accepts healthy volunteers

Chlorthalidone and HCTZ Impacts on Platelet Activation

NCT02100462
Conditions
Hypertension
Interventions
Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Aspirin 81 mg
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Coronary Artery Disease
Interventions
ticagrelor, clopidogrel
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
San Diego, California
Conditions
Healthy
Interventions
intravenous diclofenac sodium (DIC075V), ketorolac, oral diclofenac (Cataflam), aspirin
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Completed Not applicable Interventional Accepts healthy volunteers

Acute Assessment of Platelet Reactivity After the Intake of Oleocanthal

NCT03528603
Conditions
Platelet Aggregation, Nutritional and Metabolic Disease, Cardiovascular Diseases
Interventions
Oleocanthal-Rich Extra Virgin Olive Oil, Oleocanthal-low Extra Virgin Olive Oil
Other
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 45 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Davis, California
Conditions
Stroke, Brain Infarction
Interventions
Eptifibatide
Drug
Lead sponsor
Arthur Pancioli
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Edgewood, Kentucky • Florence, Kentucky • Fort Thomas, Kentucky + 1 more
Active, not recruiting Not applicable Interventional

LEADERS FREE II: BioFreedom™ Pivotal Study

NCT02843633
Conditions
Acute Coronary Syndrome, High Bleeding Risk
Interventions
BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug
Device · Drug
Lead sponsor
Biosensors Europe SA
Industry
Eligibility
Not listed
Enrollment
1,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
39
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • La Jolla, California + 34 more
Completed No phase listed Observational Accepts healthy volunteers

Aggreguide A-100 ADP Assay Evaluation

NCT02112539
Conditions
Platelet Aggregation, ADP Blockers
Interventions
platelet aggregation measurement
Other
Lead sponsor
Aggredyne, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hematologic Neoplasms, Thrombocytopenia, Anticoagulants, Platelet Aggregation Inhibitors
Interventions
Hold, Prophylactic dose antithrombotic, Change antithrombotic Drug, Change platelet transfusion threshold, Full dose antithrombotics, Mechanical measures, Intermediate dose antithrombotic
Drug · Biological · Device
Lead sponsor
Maastricht University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Pioglitazone on Platelet Function

NCT00861341
Conditions
Diabetes, Platelet Function, Healthy
Interventions
Aspirin, Pioglitazone
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, New York
Conditions
Cardiovascular Diseases, Platelet Aggregation, Spontaneous, HIV/AIDS
Interventions
Platelet aggregation
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Vascular Disease, Coronary Artery Disease Risk Factors Multiple
Interventions
PZ-128
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Ischemic Stroke, Stroke, Brain Infarction
Interventions
Eptifibatide, rt-PA
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Santa Monica, California + 11 more
Completed No phase listed Observational Accepts healthy volunteers Results available

Genetic Variation in Platelet Aggregation

NCT01576536
Conditions
Myocardial Infarction
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 45 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Bleeding
Interventions
Antithrombotics
Drug
Lead sponsor
Pain Management Center of Paducah
Other
Eligibility
18 Years and older
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Paducah, Kentucky
Conditions
MULTIPLE MYELOMA
Interventions
Velcade
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study

NCT01768637
Conditions
Chronic Kidney Disease
Interventions
Aspirin, Clopidogrel
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 90 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Systolic Heart Failure
Interventions
Prasugrel 10 mg daily x 2 weeks, Clopidogrel 75 mg daily x 2 weeks
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Purple Grape Juice Study

NCT00551746
Conditions
Cardiovascular Disease
Interventions
Purple Grape Juice
Dietary Supplement
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Murray, Utah
Completed No phase listed Observational Accepts healthy volunteers

Study to Determine Racial and Gender Differences in Platelet Aggregation

NCT00233428
Conditions
Platelet Aggregation
Interventions
Blood Draw
Procedure
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Lubbock, Texas
Conditions
Healthy Volunteer
Interventions
aleglitazar, aspirin, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas